Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Announces 2026 Priorities and Financial Update
Summary
Terns Pharmaceuticals, Inc. announced its 2026 priorities and program milestones for its lead drug TERN-701, an oral allosteric BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia (CML). Key milestones for 2026 include the selection of a pivotal dose, end of Phase 2 regulatory interaction, updated and expanded CARDINAL data, and initiation of a first pivotal trial in late 2026/early 2027. The company also reported unaudited cash, cash equivalents and marketable securities of approximately $1.0 billion for the year ended December 31, 2025, which is expected to provide runway into 2031. A presentation on these updates will be given at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.
Profitelligence Alerts
Get alerts for TERN
Be first to know when Terns Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic candidates targeting liver disease and oncology. Its primary function is to advance its pipeline of clinical and preclinical drug candidates that address significant unmet medical needs. One of the company's main focuses is on non-alcoholic steatohepatitis (NASH), a progressive liver disease. Through innovative approaches, Terns Pharmaceuticals explores various mechanisms to treat NASH, including small molecules designed to reduce liver inflammation and fibrosis. Beyond liver disease, the company is expanding its platform to include oncology, diversifying its impact in the healthcare industry. As a key player in the biopharmaceutical sector, Terns Pharmaceuticals Inc. contributes to the growing landscape of targeted therapies. With a dedicated emphasis on research and development, the company plays an essential role in pushing the boundaries of treatment options, potentially transforming the management of chronic liver diseases and cancer.
Official SEC Documents
Advertisement